Alnylam Pharmaceuticals, Inc. (ALNY) Price and Market Data

Alnylam Pharmaceuticals, Inc. is a leader in the development of RNA interference (RNAi) therapeutics, a naturally occurring cellular pathway that enables sequence-specific gene silencing and regulation of gene expression. Its commercial RNAi medicines include Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, and Oxlumo for primary hyperoxaluria type 1, all developed and marketed by Alnylam. The company’s partnered products also include Leqvio for hypercholesterolemia, commercialized by Novartis, and Qfitlia for hemophilia A or B, commercialized by Sanofi. In addition, Alnylam has a broad clinical pipeline spanning multiple therapeutic areas, including cardio-metabolic disease, neuroscience, and hematology.